Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Oncogenic BRAFV600E mutations activate MAPK signaling and are associated with treatment resistance and poor prognosis in patients with colorectal cancer. In BRAFV600E-mutant colorectal cancers, treatment failure may be related to BRAFV600E-mediated apoptosis resistance that occurs by an as yet undefined mechanism. We found that BRAFV600E can upregulate anti-apoptotic MCL-1 in a gene dose-dependent manner using colorectal cancer cell lines isogenic for BRAF. BRAFV600E-induced MCL-1 upregulation was confirmed by ectopic BRAFV600E expression that activated MEK/ERK signaling to phosphorylate (MCL-1Thr163) and stabilize MCL-1. Upregulation of MCL-1 was mediated by MEK/ERK shown by the ability of ERK siRNA to suppress MCL-1. Stabilization of MCL-1 by phosphorylation was shown by a phosphorylation-mimicking mutant and an unphosphorylated MCL-1 mutant that decreased or increased MCL-1 protein turnover, respectively. MEK/ERK inhibition by cobimetinib suppressed MCL-1 expression/phosphorylation and induced proapoptotic BIM to a greater extent than did vemurafenib in BRAFV600E cell lines. MCL-1 knockdown versus control shRNA significantly enhanced cobimetinib-induced apoptosis in vitro and in HT29 colon cancer xenografts. The small-molecule MCL-1 inhibitor, A-1210477, also enhanced cobimetinib-induced apoptosis in vitro that was due to disruption of the interaction of MCL-1 with proapoptotic BAK and BIM. Knockdown of BIM attenuated BAX, but not BAK, activation by cobimetinib plus A-1210477. In summary, BRAFV600E-mediated MEK/ERK activation can upregulate MCL-1 by phosphorylation/stabilization to confer apoptosis resistance that can be reversed by MCL-1 antagonism combined with cobimetinib, suggesting a novel therapeutic strategy against BRAFV600E-mutant CRCs. Mol Cancer Ther; 15(12); 3015–27. ©2016 AACR.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Thus, although either BCL2/BCL-w/BCL-XL or MCL1 inhibitors can synergise to some extent with ERK1/2 pathway inhibitors in a broad range of lineages11,26,27,53,54, the ability to target individual pro-survival proteins as BH3-mimetic-specificity continues to be refined will allow antagonism of only those critical pro-survival proteins that limit apoptotic responses to ERK1/2 pathway inhibitors in a”
From Targeting melanoma’s MCL1 bias unleashes the apoptotic potential of BRAF and ERK1/2 pathway inhibitors (2019) · cites this paper as [53]
In the citing paper
“MCL1 can still limit the activity of Bcl-xL inhibitors and other chemotherapeutic agents in CRC [17–19]”
From MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma (2022) · cites this paper as [18]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MAP kinase signalling pathways in cancer
Dhillon, A. S., Hagan, S., Rath, O., & Kolch, W. (2007) · Oncogene · doi:10.1038/sj.onc.1210421 · Cited by 2,995 · cited 1×
“TheMAPK pathway links extracellular signals to the machinery that controls cellular processes including apoptosis (20).”
BackgroundSurvival in BRAF V600-mutant advanced melanoma treated with vemurafenib
Sosman, J. A., Kim, K. B., Schuchter, L., Gonzalez, R., Pavlick, A. C., Weber, J. S., McArthur, G. A., Hutson, T. E., Moschos, S. J., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112302 · Cited by 2,156 · cited 1×
“Whereas approximately 50% of patients with metastatic melanoma responded to BRAF inhibition by vemurafenib, the response rate was only 5% among patients with BRAF metastatic CRC (3, 14, 15).”
BackgroundUnresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR
Prahallad, A., Sun, C., Huang, S., Di Nicolantonio, F., Salazar, R., Zecchin, D., Beijersbergen, R. L., Bardelli, A., & Bernards, R. (2012) · Nature · doi:10.1038/nature10868 · Cited by 2,051
Self-citationRAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)
Poulikakos, P. I., Persaud, Y., Janakiraman, M., Kong, X., Ng, C., Moriceau, G., Shi, H., Atefi, M., Titz, B., Gabay, M. T., et al. (2011) · Nature · doi:10.1038/nature10662 · Cited by 1,454
Corcoran, R. B., Ebi, H., Turke, A. B., Coffee, E. M., Nishino, M., Cogdill, A. P., Brown, R. D., Della Pelle, P., Dias-Santagata, D., Hung, K. E., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0341 · Cited by 1,022
Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy
Shi, H., Hugo, W., Kong, X., Hong, A., Koya, R. C., Moriceau, G., Chodon, T., Guo, R., Johnson, D. B., Dahlman, K. B., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-13-0642 · Cited by 982
Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF -Mutated Colorectal Cancer
Kopetz, S., Desai, J., Chan, E., Hecht, J. R., O'Dwyer, P. J., Maru, D., Morris, V., Janku, F., Dasari, A., Chung, W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2497 · Cited by 697 · cited 3×
“BRAF is detected in approximately 10% of human colorectal cancers (CRC) where it is associated with poor responsiveness to chemotherapy (3, 4), and poor prognosis (5–9) with frequent peritoneal metastasis (10–12).”
BackgroundCorcoran, R. B., Atreya, C. E., Falchook, G. S., Kwak, E. L., Ryan, D. P., Bendell, J. C., Hamid, O., Messersmith, W. A., Daud, A., Kurzrock, R., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.2471 · Cited by 507
Luciano, F., Jacquel, A., Colosetti, P., Herrant, M., Cagnol, S., Pages, G., & Auberger, P. (2003) · Oncogene · doi:10.1038/sj.onc.1206792 · Cited by 477 · cited 1×
“Treatment with inhibitors of MEK and BRAFwere shown to prevent the proteasomal degradation of BIM that led to apoptosis (27, 28).”
BackgroundLeverson, J. D., Zhang, H., Chen, J., Tahir, S. K., Phillips, D. C., Xue, J., Nimmer, P., Jin, S., Smith, M., Xiao, Y., et al. (2015) · Cell Death & Disease · doi:10.1038/cddis.2014.561 · Cited by 440 · cited 2×
“MCL-1 inhibitor, A-1210477, synergistically enhances cobimetinib-induced apoptosis To gain further mechanistic insight, we evaluated the smallmolecule MCL-1 inhibitor A-1210477 (34) that has been shown to demonstrate selectivity for MCL-1 in cancer cells (34).”
BackgroundMethod
Research works printed but not linked: 43
- Hatzivassiliou, 2013, Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers, Nature, 501, 232, 10.1038/nature12441 · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Roth, 2010, Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60–00 trial, J Clin Oncol, 28, 466, 10.1200/JCO.2009.23.3452 · DOI · Paper page
- Farina-Sarasqueta, 2010, The BRAF V600E mutation is an independent prognostic factor for survival in stage II and stage III colon cancer patients, Ann Oncol, 21, 2396, 10.1093/annonc/mdq258 · DOI · Paper page
- Ogino, 2012, Predictive and prognostic roles of BRAF mutation in stage III colon cancer: results from intergroup trial CALGB 89803, Clin Cancer Res, 18, 890, 10.1158/1078-0432.CCR-11-2246 · DOI · Paper page
- Sinicrope, 2015, Molecular markers identify subtypes of stage III colon cancer associated with patient outcomes, Gastroenterology, 148, 88, 10.1053/j.gastro.2014.09.041 · DOI · Paper page
- Phipps, 2015, Association between molecular subtypes of colorectal cancer and patient survival, Gastroenterology, 148, 77, 10.1053/j.gastro.2014.09.038 · DOI · Paper page
- Tie, 2011, Optimizing targeted therapeutic development: analysis of a colorectal cancer patient population with the BRAF(V600E) mutation, Int J Cancer, 128, 2075, 10.1002/ijc.25555 · DOI · Paper page
- Tran, 2011, Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer, Cancer, 117, 4623, 10.1002/cncr.26086 · DOI · Paper page
- Wilcox, 2015, Influence of molecular alterations on site-specific (ss) time to recurrence (TTR) following adjuvant therapy in resected colon cancer (CC) (Alliance Trial N0147), J Clin Oncol 33, 10.1200/jco.2015.33.15_suppl.3590 · doi:10.1200/jco.2015.33.15_suppl.3590
- Chapman, 2011, Improved survival with vemurafenib in melanoma with BRAF V600E mutation, N Engl J Med, 364, 2507, 10.1056/NEJMoa1103782 · DOI · Paper page
- Larkin, 2014, Combined vemurafenib and cobimetinib in BRAF-mutated melanoma, N Engl J Med, 371, 1867, 10.1056/NEJMoa1408868 · DOI · Paper page
- Cartlidge, 2008, Oncogenic BRAF(V600E) inhibits BIM expression to promote melanoma cell survival, Pigment Cell Melanoma Res, 21, 534, 10.1111/j.1755-148X.2008.00491.x · DOI · Paper page
- Jiang, 2008, Up-regulation of Mcl-1 is critical for survival of human melanoma cells upon endoplasmic reticulum stress, Cancer Res, 68, 6708, 10.1158/0008-5472.CAN-08-0349 · DOI · Paper page
- Boisvert-Adamo, 2008, Mutant B-RAF mediates resistance to anoikis via Bad and Bim, Oncogene, 27, 3301, 10.1038/sj.onc.1211003 · DOI
- Zhang, 2013, Role of apoptosis in colon cancer biology, therapy, and prevention, Curr Colorectal Cancer Rep, 9, 1, 10.1007/s11888-013-0188-z · DOI
- Masuoka, 2010, Clinical relevance of apoptotic regulatory proteins in colorectal cancers, Curr Colorectal Cancer Rep, 6, 111, 10.1007/s11888-010-0051-4 · DOI
- Ley, 2005, Regulatory phosphorylation of Bim: sorting out the ERK from the JNK, Cell Death Differ, 12, 1008, 10.1038/sj.cdd.4401688 · DOI · Paper page
- Lucas, 2012, Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737, Clin Cancer Res, 18, 783, 10.1158/1078-0432.CCR-11-1166 · DOI
- Frederick, 2014, Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics, PLoS One, 9, e101286, 10.1371/journal.pone.0101286 · DOI · Paper page
- Akgul, 2009, Mcl-1 is a potential therapeutic target in multiple types of cancer, Cell Mol Life Sci, 66, 1326, 10.1007/s00018-008-8637-6 · DOI · Paper page
- Huang, 2008, BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells, Cancer Res, 68, 2944, 10.1158/0008-5472.CAN-07-2508 · DOI · Paper page
- Huang, 2009, BH3 mimetic obatoclax enhances TRAIL-mediated apoptosis in human pancreatic cancer cells, Clin Cancer Res, 15, 150, 10.1158/1078-0432.CCR-08-1575 · DOI
- Ding, 2008, Down-regulation of myeloid cell leukemia-1 through inhibiting Erk/Pin 1 pathway by sorafenib facilitates chemosensitization in breast cancer, Cancer Res, 68, 6109, 10.1158/0008-5472.CAN-08-0579 · DOI · Paper page
- Phillips, 2015, Loss in MCL-1 function sensitizes non-Hodgkin's lymphoma cell lines to the BCL-2-selective inhibitor venetoclax (ABT-199), Blood Cancer J, 5, e368, 10.1038/bcj.2015.88 · DOI
- Xiao, 2015, MCL-1 Is a key determinant of breast cancer cell survival: validation of MCL-1 dependency utilizing a highly selective small molecule inhibitor, Mol Cancer Ther, 14, 1837, 10.1158/1535-7163.MCT-14-0928 · DOI · Paper page
- Rizos, 2014, BRAF inhibitor resistance mechanisms in metastatic melanoma: spectrum and clinical impact, Clin Cancer Res, 20, 1965, 10.1158/1078-0432.CCR-13-3122 · DOI · Paper page
- Van Allen, 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, Cancer Discov, 4, 94, 10.1158/2159-8290.CD-13-0617 · DOI · Paper page
- Nazarian, 2010, Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation, Nature, 468, 973, 10.1038/nature09626 · DOI · Paper page
- Welcker, 2004, The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation, Proc Natl Acad Sci U S A, 101, 9085, 10.1073/pnas.0402770101 · DOI · Paper page
- Yada, 2004, Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7, EMBO J, 23, 2116, 10.1038/sj.emboj.7600217 · DOI · Paper page
- Lin, 2002, Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase, EMBO J, 21, 4037, 10.1093/emboj/cdf406 · DOI · Paper page
- Ju, 2007, Ubiquitin-mediated degradation of Rpn4 is controlled by a phosphorylation-dependent ubiquitylation signal, Biochim Biophys Acta, 1773, 1672, 10.1016/j.bbamcr.2007.04.012 · DOI
- Becker, 2014, Mutant B-RAF-Mcl-1 survival signaling depends on the STAT3 transcription factor, Oncogene, 33, 1158, 10.1038/onc.2013.45 · DOI
- Wang, 2007, Apoptosis induction in human melanoma cells by inhibition of MEK is caspase-independent and mediated by the Bcl-2 family members PUMA, Bim, and Mcl-1, Clin Cancer Res, 13, 4934, 10.1158/1078-0432.CCR-07-0665 · DOI · Paper page
- Fofaria, 2015, Overexpression of Mcl-1 confers resistance to BRAFV600E inhibitors alone and in combination with MEK1/2 inhibitors in melanoma, Oncotarget, 6, 40535, 10.18632/oncotarget.5755 · DOI · Paper page
- Morales, 2011, Distribution of Bim determines Mcl-1 dependence or codependence with Bcl-xL/Bcl-2 in Mcl-1-expressing myeloma cells, Blood, 118, 1329, 10.1182/blood-2011-01-327197 · DOI · Paper page
- Bhalla, 2011, The novel anti-MEK small molecule AZD6244 induces BIM-dependent and AKT-independent apoptosis in diffuse large B-cell lymphoma, Blood, 118, 1052, 10.1182/blood-2011-03-340109 · DOI
- O'Reilly, 2009, MEK/ERK-mediated phosphorylation of Bim is required to ensure survival of T and B lymphocytes during mitogenic stimulation, J Immunol, 183, 261, 10.4049/jimmunol.0803853 · DOI · Paper page
- Wiggins, 2010, Refining the minimal sequence required for ERK1/2-dependent poly-ubiquitination and proteasome-dependent turnover of BIM, Cell Signal, 22, 801, 10.1016/j.cellsig.2010.01.004 · DOI
- Nguyen, 2013, When ubiquitination meets phosphorylation: a systems biology perspective of EGFR/MAPK signalling, Cell Commun Signal, 11, 52, 10.1186/1478-811X-11-52 · DOI · Paper page
- Sarosiek, 2013, BID preferentially activates BAK while BIM preferentially activates BAX, affecting chemotherapy response, Mol Cell, 51, 751, 10.1016/j.molcel.2013.08.048 · DOI · Paper page
- Bendell, 2016, Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC), J Clin Oncol 34, 10.1200/JCO.2016.34.15_suppl.3502 · DOI · Paper page
Cited by
Targeting MCL-1 in cancer: current status and perspectives
Wang, H., Guo, M., Wei, H., & Chen, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01079-1 · Cited by 301
Sale, M. J., Minihane, E., Monks, N. R., Gilley, R., Richards, F. M., Schifferli, K. P., Andersen, C. L., Davies, E. J., Vicente, M. A., Ozono, E., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-12409-w · Cited by 80
Koumaki, K., Kontogianni, G., Kosmidou, V., Pahitsa, F., Kritsi, E., Zervou, M., Chatziioannou, A., Souliotis, V. L., Papadodima, O., & Pintzas, A. (2021) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2020.166061 · Cited by 36
MCL1 nuclear translocation induces chemoresistance in colorectal carcinoma
Fu, D., Pfannenstiel, L., Demelash, A., Phoon, Y. P., Mayell, C., Cabrera, C., Liu, C., Zhao, J., Dermawan, J., Patil, D., et al. (2022) · Cell Death & Disease · doi:10.1038/s41419-021-04334-y · Cited by 29
Metadata
- Authors
- Kawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A.
- Venue
- Molecular Cancer Therapeutics
- Published
- 2016-12-01
- Volume
- 15
- Issue
- 12
- Pages
- 3015-3027
- ISSN
- 1535-7163
- 1538-8514
- Cited by
- 41
- References
- 13
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. https://app.cochat.ai/papers/10.1158/1535-7163.mct-16-0017
- The paper
- Kawakami, H., Huang, S., Pal, K., Dutta, S. K., Mukhopadhyay, D., & Sinicrope, F. A. (2016). Mutant BRAF Upregulates MCL-1 to Confer Apoptosis Resistance that Is Reversed by MCL-1 Antagonism and Cobimetinib in Colorectal Cancer. Molecular Cancer Therapeutics. https://doi.org/10.1158/1535-7163.mct-16-0017
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.